Today, EpiCept Corporation issued a notice to its stockholders for a Special meeting of Stockholders. The meeting is scheduled August 6 at the company's office. The meeting will tackle approval on merger between EpiCept Corporation and Immune Pharmaceuticals. Those who are entitled to vote at the Special Meeting are EpiCept stockholders of record at the close of trading on June 11.

Letters of notice were sent to the company's shareholders last June 19. The notice contained instructions on how to vote their shares through mail, calls or online.The merger of EpiCept and Immune Pharmaceuticals are subject to certain conditions.

EpiCept is a specialty pharmaceutical company looking for innovative technologies to fight cancer and pain. The company is based in New York. Immune Pharmaceuticals is based in Israel. It is an emerging leader in the development of Monoclonal Antibodies. This is used to treat inflammatory diseases and cancer. The development of said antibodies is most attractive in the industry with sales over US$50 billion yearly.